{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T20:45:45Z","timestamp":1791837945025,"version":"4.3.4"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01 CA225618"],"award-info":[{"award-number":["P01 CA225618"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA006973"],"award-info":[{"award-number":["P30 CA006973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtct.2026.08.051","type":"journal-article","created":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:50:48Z","timestamp":1788069048000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Donor-Related Logistical Challenges in Hematopoietic Transplantation: A Comparative Analysis of Related and Unrelated Donors"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5297-6887","authenticated-orcid":false,"given":"Frederick Ian","family":"LeMaistre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Yarkony","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander J.","family":"Ambinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Symons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8013-9886","authenticated-orcid":false,"given":"Christian B.","family":"Gocke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5225-4609","authenticated-orcid":false,"given":"Amy E.","family":"DeZern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Bola\u00f1os-Meade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth R.","family":"Cooke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravi","family":"Varadhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-1164","authenticated-orcid":false,"given":"Richard J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.08.051_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy \u2013 A Report from the CIBMTR","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"6","key":"10.1016\/j.jtct.2026.08.051_bib0002","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.bbmt.2008.03.005","article-title":"HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide","volume":"14","author":"Luznik","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2026.08.051_bib0003","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.051_bib0004","doi-asserted-by":"crossref","first-page":"933","DOI":"10.3390\/cells13110933","article-title":"The evolution of hematopoietic stem cell transplantation to overcome access disparities: the role of NMDP","volume":"13","author":"Devine","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.051_bib0005","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/bmt.2008.102","article-title":"The US National Marrow Donor Program role in unrelated donor hematopoietic cell transplantation","volume":"42","author":"Confer","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.051_bib0006","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1182\/bloodadvances.2023012385","article-title":"Racial\/ethnic disparities in availability of volunteer unrelated donors for allogeneic transplantation","volume":"8","author":"Fingrut","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.051_bib0007","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.bbmt.2014.10.002","article-title":"8\/8 and 10\/10 high-resolution match rate for the be the match unrelated donor registry","volume":"21","author":"Dehn","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.051_bib0008","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1016\/S2352-3026(18)30119-4","article-title":"Should an HLA-matched donor still be considered the perfect donor?","volume":"5","author":"Jones","year":"2018","journal-title":"Lancet Haematol"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMsa1311707","article-title":"HLA match likelihoods for hematopoietic stem-cell grafts in the U.S. Registry","volume":"371","author":"Gragert","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2026.08.051_bib0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41409-025-02740-w","article-title":"Outcomes of allogeneic hematopoietic stem cell transplantation from different donor types in primary refractory acute myeloid leukemia: a report from the ALWP of the EBMT","volume":"61","author":"Barbullushi","year":"2026","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0011","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41409-019-0722-y","article-title":"Influence of alternative donor type on early survival after hematopoietic stem cell transplantation for acute myeloid leukemia lacking a sibling donor","volume":"55","author":"Deteix","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.051_bib0012","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s12885-021-07897-3","article-title":"Early transplantation-related mortality after allogeneic hematopoietic cell transplantation in patients with acute leukemia","volume":"21","author":"Kong","year":"2021","journal-title":"BMC Cancer"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2019.101112","article-title":"Is post-transplant cyclophosphamide a true game-changer in allogeneic transplantation: the struggle to unlearn","volume":"32","author":"Jones","year":"2019","journal-title":"Best Pract Res Clin Haematol"},{"issue":"31","key":"10.1016\/j.jtct.2026.08.051_bib0014","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1200\/JCO-25-00206","article-title":"Primary results from Blood and Marrow Transplant Clinical Trials Network 1702: clinical transplant-related long-term outcomes of alternative donor allogeneic transplantation","volume":"43","author":"Lee","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.051_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2024.09.021","article-title":"Biologically randomized comparison of haploidentical versus human leukocyte antigen-matched related donor reduced-intensity conditioning hematopoietic cell transplantation","volume":"30","author":"Grunwald","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.051_bib0016","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.1182\/bloodadvances.2022007741","article-title":"HLA-matching with PTCy: a reanalysis of a CIBMTR dataset with propensity score matching and donor age","volume":"6","author":"Ambinder","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2026.08.051_bib0017","doi-asserted-by":"crossref","unstructured":"Nagler A, Kayser S, Ferhat AT, et al. Non-T-depleted haploidentical transplantation compared to allogeneic transplantation from matched siblings or unrelated donors in patients with secondary AML in first complete remission: a study from the ALWP\/EBMT. Am J Hematol. 2026;101(2):281-290.","DOI":"10.1002\/ajh.70164"},{"issue":"20","key":"10.1016\/j.jtct.2026.08.051_bib0018","doi-asserted-by":"crossref","first-page":"5306","DOI":"10.1182\/bloodadvances.2024013853","article-title":"Haploidentical vs HLA-matched sibling donor HCT with PTCy prophylaxis: HLA factors and donor age considerations","volume":"8","author":"Mehta","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.051_bib0019","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.051_bib0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1182\/bloodadvances.2025017194","article-title":"Matched unrelated vs haploidentical donor hematopoietic cell transplantation using posttransplant cyclophosphamide","volume":"10","author":"Modi","year":"2026","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.051_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.02.004","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis with nonmyeloablative conditioning for blood or marrow transplantation for myelofibrosis","volume":"28","author":"Jain","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0022","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtct.2022.12.009","article-title":"Allogeneic blood or marrow transplantation with post-transplantation cyclophosphamide for peripheral T-cell lymphoma: the importance of graft source","volume":"29","author":"Sterling","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"7","key":"10.1016\/j.jtct.2026.08.051_bib0023","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.bbmt.2019.01.034","article-title":"The concentration of total nucleated cells in harvested bone marrow for transplantation has decreased over time","volume":"25","author":"Prokopishyn","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"10.1016\/j.jtct.2026.08.051_bib0024","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/j.bbmt.2020.07.037","article-title":"Shortened-duration immunosuppressive therapy after nonmyeloablative, related HLA-haploidentical or unrelated peripheral blood grafts and post-transplantation cyclophosphamide","volume":"26","author":"DeZern","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2026.08.051_bib0025","article-title":"Personalized desensitization for donor-specific anti-HLA antibodies in allogeneic blood or marrow transplantation","author":"Gocke","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.051_bib0026","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/bloodadvances.2025016207","article-title":"In search of the perfect donor: youth must be served","volume":"9","author":"Jones","year":"2025","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.jtct.2026.08.051_bib0027","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus hla-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.051_bib0028","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.jtct.2025.11.010","article-title":"Access to allogeneic cell transplantation based on donor search prognosis: BMT CTN 1702 Trial","volume":"32","author":"Dehn","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.051_bib0029","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/bmt.2012.150","article-title":"Race\/ethnicity affects the probability of finding an HLA-A, -B, -C and -DRB1 allele-matched unrelated donor and likelihood of subsequent transplant utilization","volume":"48","author":"Pidala","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2026.08.051_bib0030","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJMoa1203517","article-title":"Peripheral-blood stem cells versus bone marrow from unrelated donors","volume":"367","author":"Anasetti","year":"2012","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.051_bib0031","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1182\/bloodadvances.2020003922","article-title":"Relationship of donor age and relationship to outcomes of haploidentical transplantation with posttransplant cyclophosphamide","volume":"5","author":"DeZern","year":"2021","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0032","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1111\/bjh.19673","article-title":"Allogeneic blood or marrow transplantation using haploidentical grandchildren donors and post-transplant cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"205","author":"Aljawai","year":"2024","journal-title":"Br J Haematol"},{"issue":"14","key":"10.1016\/j.jtct.2026.08.051_bib0033","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1182\/bloodadvances.2024014858","article-title":"Transplant outcomes using older matched sibling donors compared with young alternative donors: a CIBMTR analysis","volume":"9","author":"Nath","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.jtct.2026.08.051_bib0034","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1001\/jamaoncol.2021.6846","article-title":"Relapse and disease-free survival in patients with myelodysplastic syndrome undergoing allogeneic hematopoietic cell transplantation using older matched sibling donors vs younger matched unrelated donors","volume":"8","author":"Guru Murthy","year":"2022","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.jtct.2026.08.051_bib0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/pbc.22250","article-title":"Costs of pediatric allogeneic hematopoietic-cell transplantation","volume":"54","author":"Majhail","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.jtct.2026.08.051_bib0036","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s00277-012-1530-2","article-title":"Real-world costs of autologous and allogeneic stem cell transplantations for haematological diseases: a multicentre study","volume":"91","author":"Blommestein","year":"2012","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2026.08.051_bib0037","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41409-018-0133-5","article-title":"Cost-effectiveness analysis of haploidentical vs matched unrelated allogeneic hematopoietic stem cells transplantation in patients older than 55 years","volume":"53","author":"Debals-Gonthier","year":"2018","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2026.08.051_bib0038","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/ejh.13740","article-title":"The impact of donor type on resource utilisation and costs in allogeneic haematopoietic stem cell transplantation in the Netherlands","volume":"108","author":"van Gorkom","year":"2022","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2026.08.051_bib0039","unstructured":"National Marrow Donor Program. Transplant Center Participation Agreement for U.S. Transplant Centers. Published online October 2025."},{"issue":"2","key":"10.1016\/j.jtct.2026.08.051_bib0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s00277-018-3550-z","article-title":"Utility of allogeneic hematopoietic stem cell transplantation using international donors in a homogenous ethnic population: question in the era of various alternative donors","volume":"98","author":"Kim","year":"2019","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.jtct.2026.08.051_bib0041","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1377\/hlthaff.28.5.1395","article-title":"Setting hospital rates to control costs and boost quality: the Maryland experience","volume":"28","author":"Murray","year":"2009","journal-title":"Health Aff (Millwood)"},{"issue":"8","key":"10.1016\/j.jtct.2026.08.051_bib0042","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.jtct.2025.05.014","article-title":"Current activity trends and outcomes in hematopoietic cell transplantation and cellular therapy - a report from the CIBMTR","volume":"31","author":"Spellman","year":"2025","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006925?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726006925?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:56:09Z","timestamp":1791834969000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726006925"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S2666636726006925"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.051","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Donor-Related Logistical Challenges in Hematopoietic Transplantation: A Comparative Analysis of Related and Unrelated Donors","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.08.051","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}